Canada’s Blind Spot on Drug Safety in Pregnancy – SOGC
The Society of Obstetricians and Gynaecologists of Canada (SOGC) shared a post on LinkedIn:
“A new op-ed published in the Montreal Gazette, co-authored by SOGC CEO Dr. Diane Francoeur and SOGC member Prof. Anick Bérard, highlights a critical gap in women’s health: the lack of robust data on the safety of medications during pregnancy.
Dr. Francoeur and Prof. Bérard note that most prescription drugs approved in Canada lack adequate safety data for use in pregnancy, leaving patients and physicians to make important decisions without clear evidence.
They call for stronger national data infrastructure, sustained investment in women’s health research and better integration of real-world evidence to change behaviour and improve outcomes.
Read the full op-ed.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 13, 2026, 16:24Shanza Ghaffar: Recurrent Pregnancy Loss Beyond Diagnosis and Treatment
-
May 13, 2026, 16:16Alejandro González: A Historic Moment for the PCOS Community
-
May 13, 2026, 16:15Antonio La Marca: Where There Is Research, There Is Better Care
-
May 13, 2026, 16:06Mirjam Teboe: APS Diagnosis Faces False Positive Challenges in Lupus Anticoagulant Testing
-
May 13, 2026, 16:03The Link Between Lifestyle and Environmental Exposures and Endometriotic Phenotype – RBMO
-
May 13, 2026, 11:42Analysis of MED-12 Mutations in Uterine Leiomyomas of Nigerian Women – Fertility and Sterility
-
May 13, 2026, 11:33Anuja Dokras: SPIRE 2026 Brings Together the Global Fertility Community
-
May 13, 2026, 11:23Sean Lauber: Why Do Aneuploid Embryos Rarely Lead to Live Births?
-
May 13, 2026, 10:40Polyendocrine Metabolic Ovarian Syndrome, the New Name for PCOS – PCOS Awareness Association